{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T01:26:41Z","timestamp":1795051601274,"version":"4.10.2"},"reference-count":30,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ravulizumab (ALXN1210), a new complement C5 inhibitor, provides immediate, complete, and sustained C5 inhibition. This phase 3, open-label study assessed the noninferiority of ravulizumab to eculizumab in complement inhibitor\u2013naive adults with paroxysmal nocturnal hemoglobinuria (PNH). Patients with lactate dehydrogenase (LDH) \u22651.5 times the upper limit of normal and at least 1 PNH symptom were randomized 1:1 to receive ravulizumab or eculizumab for 183 days (N = 246). Coprimary efficacy end points were proportion of patients remaining transfusion-free and LDH normalization. Secondary end points were percent change from baseline in LDH, change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT)\u2013Fatigue score, proportion of patients with breakthrough hemolysis, stabilized hemoglobin, and change in serum free C5. Ravulizumab was noninferior to eculizumab for both coprimary and all key secondary end points (Pinf &amp;lt; .0001): transfusion avoidance (73.6% vs 66.1%; difference of 6.8% [95% confidence interval (CI), \u22124.66, 18.14]), LDH normalization (53.6% vs 49.4%; odds ratio, 1.19 [0.80, 1.77]), percent reduction in LDH (\u221276.8% vs \u221276.0%; difference [95% CI], \u22120.83% [\u22125.21, 3.56]), change in FACIT-Fatigue score (7.07 vs 6.40; difference [95% CI], 0.67 [\u22121.21, 2.55]), breakthrough hemolysis (4.0% vs 10.7%; difference [95% CI], \u22126.7% [\u221214.21, 0.18]), and stabilized hemoglobin (68.0% vs 64.5%; difference [95% CI], 2.9 [\u22128.80, 14.64]). The safety and tolerability of ravulizumab and eculizumab were similar; no meningococcal infections occurred. In conclusion, ravulizumab given every 8 weeks achieved noninferiority compared with eculizumab given every 2 weeks for all efficacy end points, with a similar safety profile. This trial was registered at www.clinicaltrials.gov as #NCT02946463.<\/jats:p>","DOI":"10.1182\/blood-2018-09-876136","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T18:35:13Z","timestamp":1543862113000},"page":"530-539","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":395,"title":["Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study"],"prefix":"10.1182","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-4166","authenticated-orcid":false,"given":"Jong Wook","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Hematology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2000-1556","authenticated-orcid":false,"given":"Flore","family":"Sicre de Fontbrune","sequence":"additional","affiliation":[{"name":"Hematology Transplant Unit, H\u00f4pital Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Wong Lee Lee","sequence":"additional","affiliation":[{"name":"Hematology Unit, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviani","family":"Pessoa","sequence":"additional","affiliation":[{"name":"Hematology, Hemorio, Rio de Janeiro, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Gualandro","sequence":"additional","affiliation":[{"name":"Department of Haematology, University of S\u00e3o Paulo Medical School, S\u00e3o Paulo, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"F\u00fcreder","sequence":"additional","affiliation":[{"name":"Division of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Ptushkin","sequence":"additional","affiliation":[{"name":"Outpatient Department for Hematology, Oncology and Chemotherapy, S. P. Botkin Hospital, Moscow, Russia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Rottinghaus","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Inc, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Volles","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Inc, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Shafner","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Inc, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Aguzzi","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Inc, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Inc, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine, University of Ulm, Ulm, Germany;"},{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg-Hessen and University Hospital Ulm, Ulm, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2020073012062696500_B1","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2020073012062696500_B2","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2020073012062696500_B3","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"key":"2020073012062696500_B4","article-title":"Soliris (eculizumab); prescribing information","author":"US Food and Drug Administration","year":"2018"},{"key":"2020073012062696500_B5","article-title":"Soliris (eculizumab); summary of product characteristics","author":"European Medicines Agency","year":"2017"},{"issue":"11","key":"2020073012062696500_B6","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria [published correction appears in Nat Biotechnol. 2007;25:1488]","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2020073012062696500_B7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.24278","article-title":"Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study","volume":"91","author":"Loschi","year":"2016","journal-title":"Am J Hematol"},{"issue":"25","key":"2020073012062696500_B8","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2020073012062696500_B9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1248\/bpb.b15-00703","article-title":"Eculizumab dosing intervals longer than 17 days may be associated with greater risk of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria","volume":"39","author":"Nakayama","year":"2016","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"2020073012062696500_B10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"2020073012062696500_B11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2020073012062696500_B12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12185-013-1346-4","article-title":"Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry","volume":"97","author":"Lee","year":"2013","journal-title":"Int J Hematol"},{"issue":"5","key":"2020073012062696500_B13","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3324\/haematol.2013.093161","article-title":"Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry","volume":"99","author":"Schrezenmeier","year":"2014","journal-title":"Haematologica"},{"issue":"22","key":"2020073012062696500_B14","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.V128.22.2428.2428","article-title":"Immediate, complete, and sustained inhibition of C5 with ALXN1210 reduces complement-mediated hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH): interim analysis of a dose-escalation study [abstract]","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2020073012062696500_B15","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1182\/blood.V126.23.4777.4777","article-title":"First in human single-ascending dose study: safety, biomarker, pharmacokinetics and exposure-response relationships of ALXN1210, a humanized monoclonal antibody to C5, with marked half-life extension and potential for significantly longer dosing intervals [abstract]","volume":"126","author":"Sahelijo","year":"2015","journal-title":"Blood"},{"key":"2020073012062696500_B16","doi-asserted-by":"crossref","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"Hill","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2020073012062696500_B17","doi-asserted-by":"crossref","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS One"},{"issue":"17","key":"2020073012062696500_B18","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/bloodadvances.2018020644","article-title":"Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b\/2 studies","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"2020073012062696500_B19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2020073012062696500_B20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","article-title":"Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system","volume":"13","author":"Yellen","year":"1997","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"2020073012062696500_B21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cncr.10245","article-title":"Fatigue in cancer patients compared with fatigue in the general United States population","volume":"94","author":"Cella","year":"2002","journal-title":"Cancer"},{"issue":"5","key":"2020073012062696500_B22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2020073012062696500_B23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3346\/jkms.2016.31.2.214","article-title":"Predictive factors of mortality in population of patients with paroxysmal nocturnal hemoglobinuria (PNH): results from a Korean PNH registry","volume":"31","author":"Jang","year":"2016","journal-title":"J Korean Med Sci"},{"key":"2020073012062696500_B24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bcmd.2017.03.013","article-title":"Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status","volume":"65","author":"Yenerel","year":"2017","journal-title":"Blood Cells Mol Dis"},{"issue":"13","key":"2020073012062696500_B25","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.293.13.1653","article-title":"The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease","volume":"293","author":"Rother","year":"2005","journal-title":"JAMA"},{"issue":"suppl 2","key":"2020073012062696500_B26","first-page":"188","article-title":"Effect of eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) patients with or without high disease activity: results from the International PNH Registry [abstract]","volume":"102","author":"Hochsmann","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"2020073012062696500_B27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2020073012062696500_B28","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/CMR.4.3.359","article-title":"Infectious diseases associated with complement deficiencies","volume":"4","author":"Figueroa","year":"1991","journal-title":"Clin Microbiol Rev"},{"issue":"suppl 1","key":"2020073012062696500_B29","first-page":"3486","article-title":"Interim analysis of safety outcomes during treatment with eculizumab: results from the International Paroxysmal Nocturnal Hemoglobinuria Registry [abstract 3486]","volume":"130","author":"Hill","year":"2017","journal-title":"Blood"},{"issue":"27","key":"2020073012062696500_B30","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/6\/530\/1750546\/blood876136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/6\/530\/1750546\/blood876136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T18:27:45Z","timestamp":1596133665000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/133\/6\/530\/260550\/Ravulizumab-ALXN1210-vs-eculizumab-in-adult"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,2,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-09-876136","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,7]]}}}